155 related articles for article (PubMed ID: 27959385)
1. Microtubule actin cross-linking factor 1, a novel target in glioblastoma.
Afghani N; Mehta T; Wang J; Tang N; Skalli O; Quick QA
Int J Oncol; 2017 Jan; 50(1):310-316. PubMed ID: 27959385
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of the Spectraplakin Protein Microtubule Actin Crosslinking Factor 1 Sensitizes Glioblastomas to Radiation.
Bonner K; Borlay D; Kutten O; Quick QA
Brain Tumor Res Treat; 2020 Apr; 8(1):43-52. PubMed ID: 32390353
[TBL] [Abstract][Full Text] [Related]
3. YKL-40 downregulation is a key factor to overcome temozolomide resistance in a glioblastoma cell line.
Akiyama Y; Ashizawa T; Komiyama M; Miyata H; Oshita C; Omiya M; Iizuka A; Kume A; Sugino T; Hayashi N; Mitsuya K; Nakasu Y; Yamaguchi K
Oncol Rep; 2014 Jul; 32(1):159-66. PubMed ID: 24842123
[TBL] [Abstract][Full Text] [Related]
4. miR-126-3p sensitizes glioblastoma cells to temozolomide by inactivating Wnt/β-catenin signaling via targeting SOX2.
Luo W; Yan D; Song Z; Zhu X; Liu X; Li X; Zhao S
Life Sci; 2019 Jun; 226():98-106. PubMed ID: 30980849
[TBL] [Abstract][Full Text] [Related]
5. PI3K inhibitor combined with miR-125b inhibitor sensitize TMZ-induced anti-glioma stem cancer effects through inactivation of Wnt/β-catenin signaling pathway.
Shi L; Fei X; Wang Z; You Y
In Vitro Cell Dev Biol Anim; 2015 Nov; 51(10):1047-55. PubMed ID: 26170223
[TBL] [Abstract][Full Text] [Related]
6. The role of microtubule actin cross-linking factor 1 (MACF1) in the Wnt signaling pathway.
Chen HJ; Lin CM; Lin CS; Perez-Olle R; Leung CL; Liem RK
Genes Dev; 2006 Jul; 20(14):1933-45. PubMed ID: 16815997
[TBL] [Abstract][Full Text] [Related]
7. PomGnT1 enhances temozolomide resistance by activating epithelial-mesenchymal transition signaling in glioblastoma.
Liu Q; Xue Y; Chen Q; Chen H; Zhang X; Wang L; Han C; Que S; Lou M; Lan J
Oncol Rep; 2017 Nov; 38(5):2911-2918. PubMed ID: 29048655
[TBL] [Abstract][Full Text] [Related]
8. Mechanical unloading reduces microtubule actin crosslinking factor 1 expression to inhibit β-catenin signaling and osteoblast proliferation.
Yin C; Zhang Y; Hu L; Tian Y; Chen Z; Li D; Zhao F; Su P; Ma X; Zhang G; Miao Z; Wang L; Qian A; Xian CJ
J Cell Physiol; 2018 Jul; 233(7):5405-5419. PubMed ID: 29219183
[TBL] [Abstract][Full Text] [Related]
9. Humanized chondroitinase ABC sensitizes glioblastoma cells to temozolomide.
Jaime-Ramirez AC; Dmitrieva N; Yoo JY; Banasavadi-Siddegowda Y; Zhang J; Relation T; Bolyard C; Wojton J; Kaur B
J Gene Med; 2017 Mar; 19(3):. PubMed ID: 28087981
[TBL] [Abstract][Full Text] [Related]
10. miR‑146b‑5p suppresses glioblastoma cell resistance to temozolomide through targeting TRAF6.
Qian Z; Zhou S; Zhou Z; Yang X; Que S; Lan J; Qiu Y; Lin Y
Oncol Rep; 2017 Nov; 38(5):2941-2950. PubMed ID: 29048680
[TBL] [Abstract][Full Text] [Related]
11. Integrin αVβ3 silencing sensitizes malignant glioma cells to temozolomide by suppression of homologous recombination repair.
Christmann M; Diesler K; Majhen D; Steigerwald C; Berte N; Freund H; Stojanović N; Kaina B; Osmak M; Ambriović-Ristov A; Tomicic MT
Oncotarget; 2017 Apr; 8(17):27754-27771. PubMed ID: 27487141
[TBL] [Abstract][Full Text] [Related]
12. Microtubule actin cross-linking factor 1, a novel potential target in cancer.
Miao Z; Ali A; Hu L; Zhao F; Yin C; Chen C; Yang T; Qian A
Cancer Sci; 2017 Oct; 108(10):1953-1958. PubMed ID: 28782898
[TBL] [Abstract][Full Text] [Related]
13. Metformin treatment reduces temozolomide resistance of glioblastoma cells.
Yang SH; Li S; Lu G; Xue H; Kim DH; Zhu JJ; Liu Y
Oncotarget; 2016 Nov; 7(48):78787-78803. PubMed ID: 27791206
[TBL] [Abstract][Full Text] [Related]
14. miR-423-5p contributes to a malignant phenotype and temozolomide chemoresistance in glioblastomas.
Li S; Zeng A; Hu Q; Yan W; Liu Y; You Y
Neuro Oncol; 2017 Jan; 19(1):55-65. PubMed ID: 27471108
[TBL] [Abstract][Full Text] [Related]
15. MALAT1 is a prognostic factor in glioblastoma multiforme and induces chemoresistance to temozolomide through suppressing miR-203 and promoting thymidylate synthase expression.
Chen W; Xu XK; Li JL; Kong KK; Li H; Chen C; He J; Wang F; Li P; Ge XS; Li FC
Oncotarget; 2017 Apr; 8(14):22783-22799. PubMed ID: 28187000
[TBL] [Abstract][Full Text] [Related]
16. miR-20a mediates temozolomide-resistance in glioblastoma cells via negatively regulating LRIG1 expression.
Wei J; Qi X; Zhan Q; Zhou D; Yan Q; Wang Y; Mo L; Wan Y; Xie D; Xie J; Yang S
Biomed Pharmacother; 2015 Apr; 71():112-8. PubMed ID: 25960225
[TBL] [Abstract][Full Text] [Related]
17. Cordycepin Augments the Chemosensitivity of Human Glioma Cells to Temozolomide by Activating AMPK and Inhibiting the AKT Signaling Pathway.
Bi Y; Li H; Yi D; Sun Y; Bai Y; Zhong S; Song Y; Zhao G; Chen Y
Mol Pharm; 2018 Nov; 15(11):4912-4925. PubMed ID: 30336060
[TBL] [Abstract][Full Text] [Related]
18. MAPK8 mediates resistance to temozolomide and apoptosis of glioblastoma cells through MAPK signaling pathway.
Xu P; Zhang G; Hou S; Sha LG
Biomed Pharmacother; 2018 Oct; 106():1419-1427. PubMed ID: 30119215
[TBL] [Abstract][Full Text] [Related]
19. Combination with TMZ and miR-505 inhibits the development of glioblastoma by regulating the WNT7B/Wnt/β-catenin signaling pathway.
Zhang C; Yang X; Fu C; Liu X
Gene; 2018 Sep; 672():172-179. PubMed ID: 29906532
[TBL] [Abstract][Full Text] [Related]
20. Toca 511 gene transfer and 5-fluorocytosine in combination with temozolomide demonstrates synergistic therapeutic efficacy in a temozolomide-sensitive glioblastoma model.
Huang TT; Hlavaty J; Ostertag D; Espinoza FL; Martin B; Petznek H; Rodriguez-Aguirre M; Ibañez CE; Kasahara N; Gunzburg W; Gruber HE; Pertschuk D; Jolly DJ; Robbins JM
Cancer Gene Ther; 2013 Oct; 20(10):544-51. PubMed ID: 23969884
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]